Kirsten Brunsvig Jarvis
- PhD student MD
- +47 23 07 45 94
Thromboembolism (TE) is a major and sometimes life threatening complication to treatment of childhood acute lymphoblastic leukemia (ALL), which is the most common pediatric malignancy. Clinical research on the topic is often hampered by underpowered studies of low quality and there is a need for international collaborative efforts to improve the level of evidence. For decades the Nordic and Baltic countries have cooperated in treatment of children with cancer within the Nordic Society of Paediatric Haematology and Oncology (NOPHO), and in 2008 the current ongoing ALL research and treatment protocol NOPHO ALL 2008 was launched. It includes nearly 100 % of the eligible children with ALL in the Nordic and Baltic countries and has prospective data registration, including toxicities, and biobanking of blood for genetic testing.
The main objective of this project is to study predisposing genetic factors, complications and outcome of TE in Nordic and Baltic children treated uniformly according to the NOPHO ALL 2008 protocol. Nearly 1500 children will be included in the study with 80 -100 of these experiencing symptomatic TE. The study will be executed within the frame of an established international collaboration at a high scientific level on a scarcely studied topic with prospects of high clinical impact for children with cancer.
Central venous line-related thromboembolism is common in children with non-high-risk acute lymphoblastic leukaemia
Acta Paediatr, 108 (6), 1167-1168
Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years
Blood, 131 (22), 2475-2484
Primary leptomeningeal melanocytosis in a 10-year-old girl: a challenging diagnosis with a poor prognosis
J Child Neurol, 26 (11), 1444-8